Did You Know That An Estimated 20% of Breast Cancers are Missed at Least Once by Mammography?1

BreastSentry is blood test that can help identify women at greater risk for breast cancer.

About the BreastSentry Test

BreastSentry measures the levels of two biomarkers, proneurotensin (pro-NT) and proenkephalin (pro-ENK), which are highly predictive of a woman’s risk for developing breast cancer. Elevated levels of pro-NT and decreased levels of pro-ENK are strong, independent risk factors for the development of breast cancer (2-5). BreastSentry provides women with additional information about breast health beyond mammography. Women with elevated BreastSentry scores may need to be referred for advanced imaging tests, such as breast MRI or Ultrasound in addition to a screening mammogram.

BreastSentry is for any woman who needs further evaluation of breast cancer risk. 

The BreastSentry Test is intended for use in women without a personal history of breast cancer. Patients with a known history of impaired renal function are not candidates for the BreastSentry test. BreastSentry needs to be prescribed by a physician and is available through the AVRT™ telehealth program. 

Contact Us Today to Learn More!

Fill out the form below and an AVRT representative will reach out to you soon to answer any questions you may have.

Name(Required)
Location
By submitting this form, you are confirming that you would like to receive information on the AVRT telehealth program. You can unsubscribe at any time.
This field is for validation purposes and should be left unchanged.

How it Works

Complete your online intake form to determine your eligibility for testing.

After you make your secure online payment for your test, we’ll schedule testing at a lab near your or arrange for a mobile phlebotomist to come to your home.

When we receive your test results, we’ll reach out to schedule a time to review them with a telehealth physician.

Additional Testing for Early Cancer Detection

In addition to the AVRT panel, we offer advanced blood tests for early cancer detection*. These tests are offered by StageZero Life Sciences, a CLIA Certified, CAP Accredited High Complexity Laboratory in Richmond, VA.  Be sure to ask your case manager about any of the tests below. Pricing and availability vary.

ARISTOTLE®

Aristotle is a blood test that uses advanced mRNA technology to identify the molecular signatures of multiple cancers from a single blood draw. (7)

Learn More

ColonSentry®

ColonSentry is a blood test that uses advanced mRNA gene expression technology to help identify Colorectal Cancer (CRC) early when it’s most treatable. (8)

Learn More

BreastSentry™

BreastSentry is a blood test that can help identify if a woman has an increased risk for developing breast cancer. (2-6)

Learn More

PHI

The Prostate Health Index is an FDA approved blood test that can help men with elevated PSA differentiate benign prostate conditions from prostate cancer. (9,10)

Learn More

* These tests are priced separately and not included in the cost of the AVRT Panel & Physician Consult.

References

  1.  https://www.cancer.gov/types/breast/mammograms-fact-sheet (Last accessed 1.22.22)
  2. Melander O, Maisel AS, Almgren P, et al. Plasma proneurotensin and incidence of diabetes, cardiovascular disease, breast cancer, and mortality. JAMA 2012;308:1469
  3. O, Belting M, Manjer J, et al. Validation of plasma proneurotensin as a novel biomarker for the prediction of incident breast cancer.  Cancer Epidemiol Biomarkers Prev. 2014 Aug;23(8):1672-6.
  4. Melander O, Orho-Melander M, Manjer J, et al. Stable Peptide of the Endogenous Opioid Enkephalin Precursor and Breast Cancer Risk. J Clin Oncol. 2015 Aug 20;33(24):2632-8
  5. Dupouy S, Mourra N, Doan VK, et al. The potential use of the neurotensin high affinity receptor 1 as a biomarker for cancer progression and as a component of personalized medicine in selective cancers. Biochimie 2011;93:1369–78
  6. Dupouy S, Viardot-Foucault V, Alifano M,  et al.  The Neurotensin Receptor-1 Pathway Contributes to Human Ductal Breast Cancer Progression. PLoS ONE 2009; 4(1): e4223. https://doi.org/10.1371/journal.pone.0004223 
  7. Dempsey A, Chao S, Stamatiou D, et al., Aristotle: A single blood test for pan-cancer screening. Journal of Clinical Oncology. 2020; 38:15_suppl, e15037-e15037
  8. Liew CC, Ma J, Tang HC, et al. The peripheral blood transcriptome dynamically reflects system wide biology: a potential diagnostic tool. J Lab Clin Med. 2006 Mar;147(3):126-32.
  9. Catalona WJ, Partin AW, Sanda MG, et al. A Multi-Center Study of [−2]Pro-Prostate-Specific Antigen (PSA) in Combination with PSA and Free PSA for Prostate Cancer Detection in the 2.0 to 10.0 ng/mL PSA Range. The Journal of Urology. 2011;185(5):1650-1655.
  10. Loeb S, Sanda MG, Broyles DL, et al. The Prostate Health Index Selectively Identifies Clinically Significant Prostate Cancer. The Journal of Urology. 2015;193(4):1163-1169

Disclaimer:
​The BreastSentry Test is intended for use in women without a personal history of breast cancer. Patients with a known history of impaired renal function are not candidates for BreastSentry. ‡The pro-NT® and pro-ENK® biomarkers are licensed from sphingotec GmbH. The BreastSentry test was developed and its performance characteristics were determined by StageZero Life Sciences Inc. It has not been cleared or approved by the U.S. Food and Drug Administration. This test is for clinical purposes. It should not be regarded as investigational or for research. This test must be ordered by and used only in consultation with a healthcare provider. This laboratory is certified under CLIA as qualified to perform high complexity clinical laboratory testing.

Aristotle, ColonSentry, & BreastSentry tests were developed, and their performance characteristics determined by Stage Zero Life Sciences, Inc.; they have not been cleared or approved by the US Food and Drug Administration. These tests were performed in a CLIA certified laboratory and are intended for clinical purposes. The Aristotle, Prostate Health Index, ColonSentry, & BreastSentry tests must be ordered by and used only in consultation with a healthcare provider.